← Back to all trials
Completed
NCT07431866
A Clinical Study of the Effect of MK-2828 on Rosuvastatin or Furosemide in Healthy People (MK-2828-005)
Conditions: Healthy
Sex: All
Ages: 24 Years – 60 Years
Healthy volunteers: Yes
Phase: PHASE1
Enrollment: 41
Sponsor: Merck Sharp & Dohme LLC
Location: Fortrea Clinical Research Unit Inc ( Site 0001) Daytona Beach Florida
Summary
Researchers are looking for other ways to treat people who have heart failure with preserved ejection fraction (HFpEF). HFpEF is a type of heart failure where the heart becomes stiff and does not relax properly. MK-2828 is a study medicine designed to treat HFpEF.
The main goal of the study is to learn if MK-2828 affects what happens to rosuvastatin or furosemide in the body.
Eligibility Criteria
Inclusion Criteria:
The main inclusion criteria include but are not limited to the following:
* Is in good health
* Has a body mass index (BMI) ≥18 and ≤32 kg/m\^2
Exclusion Criteria:
The main exclusion criteria include but are not limited to the following:
* Has a history of clinically significant endocrine, gastrointestinal, cardiovascular, hematological, hepatic, immunological, renal, respiratory, genitourinary, or major neurological abnormalities or diseases
* Has a history of cancer (malignancy)
Source: ClinicalTrials.gov (NCT07431866). StuddyBuddy aggregates publicly available trial information.
